EL7.AI
StocksMedium•6 October 2026•
1 min read

Neogen Shares Drop 7% Despite Q3 Earnings Beat as FDA Issues Product Warning

Key Facts

1Neogen reported earnings per share of $0.08, surpassing analyst estimates of $0.05.
2Company revenue reached $222.80 million, exceeding the $208.20 million estimate.
3Neogen shares declined over 7% following an FDA warning regarding a recalled equine product.

Neogen reported earnings per share of $0.08 for the third quarter, surpassing analyst estimates of $0.05 according to Financial Modeling Prep. Company revenue reached $222.80 million, exceeding the projected $208.20 million. Despite the strong financial performance, Neogen shares declined by more than 7% in a single session following a warning from the U.S. Food and Drug Administration (FDA) regarding a recalled equine product from its veterinary line.

NEOG closed at $13.01 on October 5, 2026, before facing selling pressure linked to product quality concerns and potential securities-law investigations by Levi & Korsinsky. While the company recently announced a strategic equity investment in Hinalea Imaging Corp to enhance food safety solutions, the regulatory warning regarding the HYCOAT product weighed heavily on investor sentiment.